17β-estradiol/progesterone in a single, oral, softgel capsule (TX-001HR) significantly increased the number of vasomotor symptom-free days in the REPLENISH trial

OBJECTIVE: To examine responder rates and vasomotor symptom-free days with oral 17β-estradiol/progesterone (E2/P4; TX-001HR) versus placebo in the REPLENISH trial. METHODS: REPLENISH (NCT01942668) was a phase 3, randomized, double-blind, placebo-controlled, multicenter trial, evaluating single, oral...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Menopause
Main Authors: Kaunitz, Andrew M., Bitner, Diana, Constantine, Ginger D., Bernick, Brian, Graham, Shelli, Mirkin, Sebastian
Formato: Artigo
Idioma:Inglês
Publicado: Lippincott Williams & Wilkins 2020
Assuntos:
Original Studies
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7709918/
https://ncbi.nlm.nih.gov/pubmed/32740481
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/GME.0000000000001615
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares